N(1)-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice - PubMed (original) (raw)
N(1)-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice
Oliwia Andries et al. J Control Release. 2015.
Abstract
Messenger RNA as a therapeutic modality is becoming increasingly popular in the field of gene therapy. The realization that nucleobase modifications can greatly enhance the properties of mRNA by reducing the immunogenicity and increasing the stability of the RNA molecule (the Kariko paradigm) has been pivotal for this revolution. Here we find that mRNAs containing the N(1)-methylpseudouridine (m1Ψ) modification alone and/or in combination with 5-methylcytidine (m5C) outperformed the current state-of-the-art pseudouridine (Ψ) and/or m5C/Ψ-modified mRNA platform by providing up to ~44-fold (when comparing double modified mRNAs) or ~13-fold (when comparing single modified mRNAs) higher reporter gene expression upon transfection into cell lines or mice, respectively. We show that (m5C/)m1Ψ-modified mRNA resulted in reduced intracellular innate immunogenicity and improved cellular viability compared to (m5C/)Ψ-modified mRNA upon in vitro transfection. The enhanced capability of (m5C/)m1Ψ-modified mRNA to express proteins may at least partially be due to the increased ability of the mRNA to evade activation of endosomal Toll-like receptor 3 (TLR3) and downstream innate immune signaling. We believe that the (m5C/)m1Ψ-mRNA platform presented here may serve as a new standard in the field of modified mRNA-based therapeutics.
Keywords: 5-methylcytidine (PubChem CID: 92918); Antiviral innate immunity; Gene therapy; Modified RNA; N(1)-methylpseudouridine (PubChem CID: 99543); Nucleobase modifications; Toll-like receptor; mRNA; pseudouridine (PubChem CID: 15047).
Copyright © 2015 Elsevier B.V. All rights reserved.
Similar articles
- N 1-Methylpseudouridine substitution enhances the performance of synthetic mRNA switches in cells.
Parr CJC, Wada S, Kotake K, Kameda S, Matsuura S, Sakashita S, Park S, Sugiyama H, Kuang Y, Saito H. Parr CJC, et al. Nucleic Acids Res. 2020 Apr 6;48(6):e35. doi: 10.1093/nar/gkaa070. Nucleic Acids Res. 2020. PMID: 32090264 Free PMC article. - Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes.
Pardi N, Tuyishime S, Muramatsu H, Kariko K, Mui BL, Tam YK, Madden TD, Hope MJ, Weissman D. Pardi N, et al. J Control Release. 2015 Nov 10;217:345-51. doi: 10.1016/j.jconrel.2015.08.007. Epub 2015 Aug 8. J Control Release. 2015. PMID: 26264835 Free PMC article. - Co-delivery of nucleoside-modified mRNA and TLR agonists for cancer immunotherapy: Restoring the immunogenicity of immunosilent mRNA.
Verbeke R, Lentacker I, Wayteck L, Breckpot K, Van Bockstal M, Descamps B, Vanhove C, De Smedt SC, Dewitte H. Verbeke R, et al. J Control Release. 2017 Nov 28;266:287-300. doi: 10.1016/j.jconrel.2017.09.041. Epub 2017 Oct 5. J Control Release. 2017. PMID: 28987878 - Pseudouridine and _N_1-methylpseudouridine as potent nucleotide analogues for RNA therapy and vaccine development.
Ho LLY, Schiess GHA, Miranda P, Weber G, Astakhova K. Ho LLY, et al. RSC Chem Biol. 2024 Mar 19;5(5):418-425. doi: 10.1039/d4cb00022f. eCollection 2024 May 8. RSC Chem Biol. 2024. PMID: 38725905 Free PMC article. Review. - Pseudouridine in RNA: what, where, how, and why.
Charette M, Gray MW. Charette M, et al. IUBMB Life. 2000 May;49(5):341-51. doi: 10.1080/152165400410182. IUBMB Life. 2000. PMID: 10902565 Review.
Cited by
- N1-methylpseudouridine modification level correlates with protein expression, immunogenicity, and stability of mRNA.
Chen S, Liu Z, Cai J, Li H, Qiu M. Chen S, et al. MedComm (2020). 2024 Sep 17;5(10):e691. doi: 10.1002/mco2.691. eCollection 2024 Oct. MedComm (2020). 2024. PMID: 39290255 Free PMC article. No abstract available. - N1-Methylpseudouridine and pseudouridine modifications modulate mRNA decoding during translation.
Monroe J, Eyler DE, Mitchell L, Deb I, Bojanowski A, Srinivas P, Dunham CM, Roy B, Frank AT, Koutmou KS. Monroe J, et al. Nat Commun. 2024 Sep 16;15(1):8119. doi: 10.1038/s41467-024-51301-0. Nat Commun. 2024. PMID: 39284850 Free PMC article. - Current landscape of mRNA technologies and delivery systems for new modality therapeutics.
Lu RM, Hsu HE, Perez SJLP, Kumari M, Chen GH, Hong MH, Lin YS, Liu CH, Ko SH, Concio CAP, Su YJ, Chang YH, Li WS, Wu HC. Lu RM, et al. J Biomed Sci. 2024 Sep 10;31(1):89. doi: 10.1186/s12929-024-01080-z. J Biomed Sci. 2024. PMID: 39256822 Free PMC article. Review. - Non-viral approaches in CAR-NK cell engineering: connecting natural killer cell biology and gene delivery.
McErlean EM, McCarthy HO. McErlean EM, et al. J Nanobiotechnology. 2024 Sep 10;22(1):552. doi: 10.1186/s12951-024-02746-4. J Nanobiotechnology. 2024. PMID: 39256765 Free PMC article. Review. - Macrophage manufacturing and engineering with 5'-Cap1 and N1-methylpseudouridine-modified mRNA.
Zhang P, Wang Y, Jiang J, Yang C, Liu X, Lei T, Meng X, Yang J, Ding P, Chen J, Li Q. Zhang P, et al. Mol Ther Methods Clin Dev. 2024 Jul 31;32(3):101307. doi: 10.1016/j.omtm.2024.101307. eCollection 2024 Sep 12. Mol Ther Methods Clin Dev. 2024. PMID: 39229455 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials